Welcome to our dedicated page for Oncolytics Biotech SEC filings (Ticker: ONCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oncolytics Biotech, Inc. (ONCY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational intravenously delivered double-stranded RNA immunotherapeutic agent for pancreatic, breast, and gastrointestinal cancers. Its filings help investors understand how the company describes its programs, capital plans, and corporate structure.
Oncolytics files a range of documents, including Forms 6-K and 8-K that furnish or report material events and press releases. Recent 6-K reports have included information on the formation and expansion of a Gastrointestinal Tumor Scientific Advisory Board, progress toward pivotal and registration-directed studies in pancreatic, colorectal, and anal cancers, and details of an at-the-market sales agreement used to fund pelareorep’s clinical development and general corporate purposes. A Form 8-K has reported leadership appointments in strategy, operations, and biostatistics intended to support late-stage clinical execution.
Filings also describe corporate and jurisdictional changes, such as the proposed domestication from Alberta, Canada, to the State of Nevada in the United States, the company’s transition from foreign private issuer status to domestic issuer status, and related proxy and registration materials. These documents outline the rationale for reducing regulatory complexity, aligning domicile with U.S.-based operations and shareholders, and improving access to U.S. capital markets.
On Stock Titan, investors can review these SEC filings alongside AI-powered summaries that highlight key points, such as clinical trial plans, financing arrangements, and governance changes. Real-time updates from EDGAR, combined with AI explanations of complex documents like registration statements and current reports, help users quickly understand how ONCY’s regulatory disclosures relate to its immuno-oncology strategy and pelareorep development programs.
Oncolytics Biotech Inc. filed a Form 6-K that includes a press release announcing three new members to its gastrointestinal Tumor Scientific Advisory Board: Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris. These globally recognized GI oncologists will advise on the development of pelareorep, the company’s investigational immunotherapy, across pancreatic, colorectal, and anal cancers.
The company highlights aggregated clinical data suggesting higher overall survival and response rates for pelareorep-based regimens versus historical benchmarks in first-line pancreatic cancer, squamous cell anal carcinoma, and KRAS-mutant metastatic colorectal cancer. Oncolytics states it is planning pivotal studies in all three indications, intends to continue engaging with the FDA where needed, and notes that its metastatic pancreatic and breast cancer programs with pelareorep have received Fast Track designation.
Oncolytics Biotech Inc. established an at-the-market program to sell up to $50.0 million of common shares through BTIG, LLC, which may be sold from time to time under a shelf registration on Form F-3 and an accompanying prospectus supplement. The company will pay a 3.0% commission on gross proceeds, and either party may terminate the agreement on 10 days’ notice.
Any net proceeds will be used to fund clinical development of pelareorep, related R&D, operating costs, working capital and general corporate purposes. The company states that no shares may be offered or sold in Canada.
Separately, the company filed a Form F-4 for a planned domestication from Alberta, Canada to Nevada, intended to be effective when it ceases to be a foreign private issuer on January 1, 2026 or as soon as practicable thereafter. The company cites perceived benefits of Nevada’s corporate law but notes there is no assurance the domestication will occur on the expected timeline or deliver the anticipated benefits.
Oncolytics Biotech Inc. filed a Form F-4 and sent a combined management information circular and prospectus seeking shareholder approvals to change its jurisdiction in two steps: first a continuance from Alberta to British Columbia, then a domestication to Nevada, and to adopt the 2025 Incentive Award Plan. Each step is subject to the required shareholder vote and the Board’s discretion to proceed.
If completed, each outstanding common share will continue as one share through the Continuance and become one share of Oncolytics Nevada common stock without any surrender or exchange. The company’s shares will continue to trade on Nasdaq under ONCY. Dissent rights are available under Alberta and British Columbia law as described, and the filing includes risk factors and tax considerations related to the redomiciliation.
Oncolytics Biotech Inc. (ONCY) launched an at-the-market offering of up to $50,000,000 in common shares through BTIG, LLC, which may act as sales agent or principal. Sales may be made from time to time in transactions deemed an “at the market offering” under Rule 415.
The Agent will receive a 3.0% commission on gross proceeds. On October 16, 2025, ONCY last traded at $1.17 per share on Nasdaq. The company intends to use net proceeds to fund clinical development of pelareorep, associated R&D, operating costs, working capital and general corporate purposes.
As context, common shares outstanding were 97,407,903 as of June 30, 2025. Assuming sales at $1.17, the company illustrates up to 42,735,042 shares sold, with up to 140,142,945 shares outstanding immediately after the offering. Under that assumption, the filing shows an immediate dilution of $0.79 per share to new investors at the assumed price.